Jasper Therapeutics (JSPR) Set to Post Earnings on Monday

Jasper Therapeutics (NASDAQ:JSPR) is expected to be posting its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $6.00 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, analysts expect Jasper Therapeutics to post ($0.94) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $0.52 on Monday. The stock’s 50-day moving average is $0.60 and its 200 day moving average is $0.86. Jasper Therapeutics has a one year low of $0.32 and a one year high of $2.42. The firm has a market cap of $17.31 million, a price-to-earnings ratio of -0.33 and a beta of 3.30.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JSPR. William Blair assumed coverage on shares of Jasper Therapeutics in a report on Wednesday, October 14th. They set an “outperform” rating on the stock. Wall Street Zen upgraded Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Piper Sandler initiated coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $7.33.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.